Data as of Q4 2025 (Dec 31, 2025)

Propel Bio Management, LLC

โ€ขCIK: 1969764โ€ขFiling: Q4 2025

**Propel Bio Management, LLC** is a specialized investment vehicle managing $117M across a portfolio of 20 holdings. The fund exhibits a concentrated focus on the biotechnology sector, with its largest allocation at PAGP ($24.4M). Key positions also include SP4P ($18.8M) and PHAT ($12.3M), representing significant exposure to high-growth life science opportunities. This structure suggests a deep, conviction-driven approach within the biotech value chain.

Total AUM
$117.1M
QoQ Performance
+17.3%
Positions
20
Top 10 Concentration
83.9%
Latest Filing
Q4 2025

Top Holdings Allocation

PAGP
SP4P
PHAT
VRDN
MIST
KYTX
CMPS
PAGP20.8%
SP4P16.1%
PHAT10.5%
VRDN7.5%
MIST7.1%
KYTX5.4%
CMPS5.1%
IVA4.0%

๐Ÿ“ˆ Biggest Buys

KYTX
KYVERNA THERAPEUTICS INC
NEW
5.4% of portfolio
VRDN
VIRIDIAN THERAPEUTICS INC
+213.9%
7.5% of portfolio
IVA
INVENTIVA SA - ADR
NEW
4.0% of portfolio
โ€”
OCULIS HOLDING AG
NEW
2.9% of portfolio
PHAT
PHATHOM PHARMACEUTICALS INC
+34.0%
10.5% of portfolio

๐Ÿ“‰ Biggest Sells

MIST
MILESTONE PHARMACEUTICALS
-19.6%
7.1% of portfolio
ZVRA
ZEVRA THERAPEUTICS INC
-72.5%
0.5% of portfolio
ABEO
ABEONA THERAPEUTICS INC
-14.7%
3.7% of portfolio
TCE2
CELLDEX THERAPEUTICS INC
-0.5%
3.6% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

AKRO
AKERO THERAPEUTICS INC
SOLD
$10.9M
APLT
APPLIED THERAPEUTICS INC
SOLD
$6.8M
TCRX
TSCAN THERAPEUTICS INC
SOLD
$3.5M
JSPR
JASPER THERAPEUTICS INC
SOLD
$2.4M

Changes from Q3 2025

NEW8 new positions
โ†‘4 increased
โ†“4 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023